Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) have received an average rating of “Buy” from the thirteen ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $35.00.
ALDR has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Alder Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, July 11th. Credit Suisse Group lowered shares of Alder Biopharmaceuticals from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $30.00 to $17.00 in a research note on Wednesday, June 28th. Jefferies Group LLC restated a “buy” rating and set a $43.00 target price on shares of Alder Biopharmaceuticals in a research note on Thursday, March 30th. Needham & Company LLC initiated coverage on shares of Alder Biopharmaceuticals in a research note on Monday, May 15th. They set a “buy” rating and a $36.00 target price on the stock. Finally, Wells Fargo & Company restated an “outperform” rating and set a $51.00 target price on shares of Alder Biopharmaceuticals in a research note on Wednesday, June 28th.
TRADEMARK VIOLATION WARNING: “Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Given Average Rating of “Buy” by Brokerages” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://stocknewstimes.com/2017/07/19/alder-biopharmaceuticals-inc-nasdaqaldr-given-average-rating-of-buy-by-brokerages.html.
Alder Biopharmaceuticals (ALDR) traded up 3.90% during mid-day trading on Friday, hitting $12.00. 2,958,186 shares of the stock were exchanged. The company has a 50 day moving average of $14.94 and a 200 day moving average of $19.54. Alder Biopharmaceuticals has a 12-month low of $10.05 and a 12-month high of $36.48. The firm’s market cap is $604.92 million.
Alder Biopharmaceuticals (NASDAQ:ALDR) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.95) by $1.04. During the same period in the previous year, the firm posted ($0.76) EPS. On average, equities analysts anticipate that Alder Biopharmaceuticals will post ($6.27) earnings per share for the current fiscal year.
In other news, Director Stephen M. Dow acquired 25,000 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The stock was acquired at an average cost of $10.00 per share, with a total value of $250,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.60% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of ALDR. Fox Run Management L.L.C. purchased a new stake in Alder Biopharmaceuticals during the second quarter valued at $402,000. Nuveen Asset Management LLC increased its stake in Alder Biopharmaceuticals by 36.6% in the first quarter. Nuveen Asset Management LLC now owns 66,224 shares of the biopharmaceutical company’s stock valued at $1,377,000 after buying an additional 17,760 shares during the last quarter. Janus Capital Management LLC increased its stake in Alder Biopharmaceuticals by 4.7% in the first quarter. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company’s stock valued at $107,473,000 after buying an additional 230,044 shares during the last quarter. Credit Suisse AG increased its stake in Alder Biopharmaceuticals by 19.8% in the first quarter. Credit Suisse AG now owns 243,807 shares of the biopharmaceutical company’s stock valued at $5,071,000 after buying an additional 40,260 shares during the last quarter. Finally, Redmile Group LLC increased its stake in Alder Biopharmaceuticals by 107.5% in the first quarter. Redmile Group LLC now owns 1,909,886 shares of the biopharmaceutical company’s stock valued at $39,726,000 after buying an additional 989,336 shares during the last quarter.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
